FindTrial
Sign In

The mechanism of proprotein convertase Subtilisin/kexin type 9 promoting the progression of calcific aortic valve disease

The mechanism of proprotein convertase Subtilisin/kexin type 9 promoting the progression of calcific aortic valve disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-COC-15006428
Enrollment
Unknown
Registered
2015-05-19
Start date
2015-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

calcific aortic valve disease

Interventions

CAVD group and control group:no

Sponsors

Tianjin Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients older than 40 years of age with calcific aortic valve disease.

Exclusion criteria

Exclusion criteria: child-bearing potential without contraception, active or chronic liver disease, a history of alcohol or drug abuse, statin therapy.

Design outcomes

Primary

MeasureTime frame
proprotein convertase Subtilisin/kexin type 9;lipid;Hcy;hsCRP;ALP;—

Countries

China

Contacts

Public ContactHongliang Cong
hongliangcong@126.com+86 13702102871

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026